Dogecoin Cash, Inc. (DOGP) Stock

About Dogecoin Cash, Inc.

Dogecoin Cash, Inc., through its various divisions, offers online telemedicine referral services, enabling clients across the United States to obtain medical marijuana cards. A central offering is PrestoDoctor, a digital healthcare platform that facilitates virtual connections between individuals and licensed physicians via video conferencing for securing medical cannabis recommendations. Beyond its telehealth operations, the company is engaged in the creation of several product lines. These encompass lozenges crafted for relief, "Recover" — a potent, deeply penetrating therapeutic balm designed to ease discomfort in sore muscles, joints, and conditions like arthritis or back pain — and "Trauma Cream," a topical solution infused with a blend of cannabinoids and THC. Furthermore, Dogecoin Cash, Inc. intends to introduce high-end men's and women's fashion from various suppliers through its e-commerce site, www.cbds.com. The firm also holds intellectual property licenses pertaining to the production of medical cannabis edibles. Its business endeavors primarily target both the cannabidiol (CBD) and broader cannabis sectors. The entity, previously known as Cannabis Sativa, Inc., adopted the name Dogecoin Cash, Inc. in November 2024 and is headquartered in Mesquite, Nevada.

Dogecoin Cash, Inc. is headquartered in US.

Dogecoin Cash, Inc. (DOGP) stock trades at $0.01 with a market capitalization of $1.35M. The stock is valued at a price-to-earnings (P/E) ratio of 0.12, price-to-book of -0.67, price-to-sales of 1.81. Over the past 52 weeks the stock has ranged between $0.01 and $0.07, and currently trades 85.7% below its 52-week high.

On profitability, Dogecoin Cash, Inc. generates a return on equity (ROE) of 36.10% — well above the market average, a sign of a high-quality business, return on capital employed of -45.72%, an operating margin of -80.59%, a net profit margin of -89.27%.

Official website: www.dogecoincashinc.com